Literature DB >> 4027472

Comparison of negative inotropic potency, reversibility, and effects on calcium influx of six calcium channel antagonists in cultured myocardial cells.

W H Barry, J D Horowitz, T W Smith.   

Abstract

The negative inotropic effects of calcium channel antagonists on the myocardium were used as a standard for the definition and determination of potency of this group of drugs. The effects of six calcium channel antagonists (verapamil, methoxyverapamil (D600), nifedipine, lidoflazine, perhexiline and diltiazem) were compared on cultured chick embryo ventricular cells. Drug concentrations producing 50% inhibition of contractile amplitude, derived from linearized concentration-response curves, varied from 2.8 X 10(-8)M for nifedipine to 8.3 X 10(-7)M for perhexiline. Equipotent negative inotropic concentrations of verapamil, D600, perhexiline, diltiazem and lidoflazine produced a similar inhibitory effect on 45Ca uptake into cultured cells. Nifedipine produced no significant inhibition of 45Ca uptake. The time required for recovery of contractility after cessation of drug superfusion varied in the order lidoflazine greater than perhexiline greater than D600 greater than verapamil greater than nifedipine greater than diltiazem. This relative order accords closely with the reported in vivo half-lives of these drugs. It is concluded that while some inhibition of 45Ca2+ uptake into cardiac cells can be demonstrated with five of the six calcium channel blockers studied, the relationship between the degree of inhibition of calcium influx and negative inotropic effects may not be uniform for all calcium channel antagonists.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027472      PMCID: PMC1916780          DOI: 10.1111/j.1476-5381.1985.tb08830.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium.

Authors:  M Kohlhardt; A Fleckenstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-07       Impact factor: 3.000

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

Review 3.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.

Authors:  A Fleckenstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

4.  Calcium current channels induced by catecholamines in chick embryonic hearts whose fast sodium channels are blocked by tetrodotoxin or elevated potassium.

Authors:  K Shigenobu; N Sperelakis
Journal:  Circ Res       Date:  1972-12       Impact factor: 17.367

5.  Drugs and the heart. III. Calcium antagonists.

Authors:  L H Opie
Journal:  Lancet       Date:  1980-04-12       Impact factor: 79.321

6.  "Calcium influx blockers" and vascular smooth muscle: do we really understand the mechanisms?

Authors:  R Zelis; S F Flaim
Journal:  Ann Intern Med       Date:  1981-01       Impact factor: 25.391

7.  Inhibition of sodium channels by D600.

Authors:  J B Galper; W A Catterall
Journal:  Mol Pharmacol       Date:  1979-01       Impact factor: 4.436

8.  Effects of graded hypoxia on contraction of cultured chick embryo ventricular cells.

Authors:  W H Barry; J Pober; J D Marsh; S R Frankel; T W Smith
Journal:  Am J Physiol       Date:  1980-11

9.  Effects of atrio-ventricular conduction of calcium-antagonistic coronary vasodilators, local anaesthetics and quinidine injected into the posterior and the anterior septal artery of the atrio-ventricular node preparation of the dog.

Authors:  A Narimatsu; N Taira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-08       Impact factor: 3.000

10.  Pharmacology of agents that affect calcium. Agonists and antagonists.

Authors:  D J Triggle; V C Swamy
Journal:  Chest       Date:  1980-07       Impact factor: 9.410

View more
  7 in total

Review 1.  Myocardial uptake of drugs and clinical effects.

Authors:  J D Horowitz; A C Powell
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

Review 2.  Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective.

Authors:  Andrew A Wolff; Heschi H Rotmensch; William C Stanley; Roberto Ferrari
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

3.  Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate.

Authors:  B D Walker; S M Valenzuela; C B Singleton; H Tie; J A Bursill; K R Wyse; M R Qiu; S N Breit; T J Campbell
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

4.  Stereoselective handling of perhexiline: implications regarding accumulation within the human myocardium.

Authors:  Cher-Rin Chong; Nigel E Drury; Giovanni Licari; Michael P Frenneaux; John D Horowitz; Domenico Pagano; Benedetta C Sallustio
Journal:  Eur J Clin Pharmacol       Date:  2015-09-16       Impact factor: 2.953

5.  Different negative inotropic activity of Ca2(+)-antagonists in human myocardial tissue.

Authors:  R H Schwinger; M Böhm; E Erdmann
Journal:  Klin Wochenschr       Date:  1990-08-17

6.  Relationship between plasma, atrial and ventricular perhexiline concentrations in humans: insights into factors affecting myocardial uptake.

Authors:  Nigel E Drury; Giovanni Licari; Cher-Rin Chong; Neil J Howell; Michael P Frenneaux; John D Horowitz; Domenico Pagano; Benedetta C Sallustio
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

7.  Anaesthetic tricaine acts preferentially on neural voltage-gated sodium channels and fails to block directly evoked muscle contraction.

Authors:  Seetharamaiah Attili; Simon M Hughes
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.